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Despite the best available medical treatments, many patients continue to be disabled by neurologic and
psychiatric disorders, resulting in a large unmet need. Advances in imaging and neurophysiology over the
last two decades have led to a reinterpretation of some neurologic and psychiatric conditions as primarily
disorders of circuit function, or ‘‘circuitopathies.’’ These developments have been accompanied by advances
in neurosurgical techniques with the increasingly widespread utilization of deep brain stimulation (DBS) to
recalibrate dysfunctional circuits. The versatility of DBS as both a probe and modulator of neural circuits
is making it a powerful tool to study the human brain, helping provide important details of the pathophysi-
ology of circuit dysfunction. We are currently in a phase of active investigation to determine which circuits
and disorders could be treated with DBS. Here we review recent advances in the DBS field and discuss
potential future directions in targeted intracranial neuromodulation.Introduction
The burden of neurological and psychiatric illness in society is
substantial and will increase at a rapid rate in the next few
decades (WHO, 2004). While our understanding of the specific
causes and consequences of disorders affecting the human
cerebrum is still at an early stage, recent developments in brain
imaging and neurophysiology have led to important insights into
the mechanisms underlying the clinical manifestations of these
disorders. Such studies have provided strong evidence that
many of the signs and symptoms we see in patients arise as
a consequence of disordered activity in neural circuits (Bonelli
and Cummings, 2007). This supports the notion that the
clinical manifestations in patients with common neurological
and psychiatric conditions, for example, Parkinson’s disease
(PD), major depressive disorder (MDD), and Alzheimer’s disease
(AD), reflect underlying dysregulation and malfunction in specific
brain networks subserving motor, mood, and cognitive function,
respectively (Dickerson and Eichenbaum, 2010; Price and
Drevets, 2010; Shin and Liberzon, 2010; Wichmann et al., 2011).
The etiologies of circuit disturbances are varied and include
damage to neural pathways, loss of neural elements and popu-
lations, as well as disturbances in the functional activity of neural
circuits, through disordered firing and pathological oscillatory
activity in neuron ensembles. These disturbances can be tempo-
rary or permanent, intermittent and paroxysmal. They can affect
multiple spatially and temporally separated cerebral circuits
and produce a great variety of behavioral readouts that help
clinicians diagnose, classify, and treat. It is convenient to think
of a ‘‘symptomatotopy’’ with each of the individual elements in
the constellation of symptoms in these complex disorders
mapping onto a specific neural circuit or subcircuit.
The introduction of electrodes and the application of thera-
peutic electrical stimulation within dysfunctional circuits not
only allow alleviation of symptoms but also present the unique
opportunity for probing the function of these circuits. In so doing,406 Neuron 77, February 6, 2013 ª2013 Elsevier Inc.deep brain stimulation (DBS) offers a portal into theworkings and
dynamics of brain circuits in relation to behavior and cognition.
For certain patients who have failed conventional therapies,
DBS can provide striking benefits (Holtzheimer and Mayberg,
2011; Hariz, 2012). As a result, the promise of DBS has led to
its widespread investigation. According to Medtronic, a promi-
nent supplier of DBS devices, the number of patients that
received surgery is estimated to have exceeded 100,000 world-
wide. Notably, the realization of the shared underlying patholog-
ical processes at work and the examination of DBS as a potential
treatment for a large number of brain disorders have contributed
to a rapprochement of the hitherto arbitrarily separated fields of
neurology and psychiatry. It has also contributed to a scientific
renaissance in systems neuroscience. What was a relatively
obscure field 30 years ago is now an area of active scientific
enquiry with over 700 DBS-related manuscripts being published
yearly (Figure 1). Here we outline the current state of knowledge
of DBS, including what is known about its mechanisms of action
as well as how it has been used to study and modulate activity in
dysfunctional neural circuits in patients with neurological and
psychiatric disorders.
What Is Deep Brain Stimulation?
The implantation of DBS electrodes is a neurosurgical proce-
dure, often performed under local anesthesia with patients fully
awake to facilitate precise stimulation mapping. After placement
of the electrodes in the desired target below the convexity of the
brain, they are connected to a programmable pulse generator,
similar to modern cardiac pacemakers, that is implanted under
the skin below the collarbone. Once implanted, DBS devices
can be accessed externally and stimulation settings titrated to
clinical effects. Electrical stimulation can be finely adjusted to
maximize clinical benefits and avoid off-target spread of current
or unwanted adverse effects. Modifiable variables include the
selection of the optimal contact within the electrode array, the
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Figure 1. Yearly Growth in the Number of
DBS Publications from 1980 to 2011
Significant DBS milestones since 1980 are shown
superimposed on the graph. MPTP, 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine; STN, sub-
thalamic nucleus; PD, Parkinson’s disease; FDA,
Food and Drug Administration; HDE, Humanitarian
Device Exemption; ET, essential tremor; OCD,
obsessive-compulsive disorder; MS, multiple
sclerosis.
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Reviewchoice of bipolar or monopolar stimulation, the frequency of
stimulation (typically in the high-frequency range [130–180 Hz]
for most contemporary applications), amplitude, and pulse
width. The stimulation can also be rapidly cycled on and off for
fractions of a second to several seconds. Most commonly,
stimulation is delivered continuously around the clock. An
important feature is that DBS therapy can be masked, with
patients randomly assigned to either stimulation ‘‘ON’’ or
‘‘OFF’’ in a blinded fashion. This design, allowing either active
or sham stimulation, facilitates double-blind controlled clinical
trials, in which the effect of placebo and microlesioning from
electrode insertion can be assessed (Mallet et al., 2008; Holtz-
heimer et al., 2012). Depending on the settings, the implanted
batteries can last up to 4 or 5 years. For clinical indications
requiring high outputs leading to more rapid battery depletion,
rechargeable pulse generators are now also available.
In assessing the risk-benefit balance, it is important to know
that DBS can also be associated with important operative and
perioperative risks. DBS adverse effects can be related to the
surgical procedure, to the application of stimulation, or to the
long-term consequences of implanted hardware. Serious or
life-threatening adverse events, such as brain hemorrhage, are
rare, occurring in less than 1%–2% of patients, with less serious,
typically reversible events, such as wound infection and stimula-
tion-related side effects, occurring in up to 9% of patients
(Hamani et al., 2008).
The importance of DBS to neuroscientists stemsprimarily from
its duality as both a probe and modulator of neuronal activity
(Lozano et al., 2010). During physiological mapping for the
selection of the optimal brain target for electrode placement,
surgeons can record activity from single or populations of
neurons, at rest as well as in response to various motor and
cognitive tasks (Davis et al., 2005; Androulidakis et al., 2008;
Sheth et al., 2012). This is generating a wealth of data that is
advancing our understanding of the anatomy and circuitry of
neurological and psychiatric conditions. Microelectrode record-
ings along brain trajectories in awake humans allow the identifi-Neuron 77cation of electrophysiological signatures
of target neurons and reveal how they are
involved in regulating diverse functions
such as movement (Hutchison et al.,
1998), pain (Hutchison et al., 1999), reward
(Zaghloul et al., 2009), decision making
(Sheth et al., 2012), and plasticity (Davis
et al., 1998). Another opportunity comes
from the ability to have theDBSelectrodes
externalized and to record local fieldpotentials from DBS contacts placed within deep brain struc-
tures. This approach is leading to important findings including
characterization of pathological activity such as beta oscillations
in the subthalamic nucleus (STN) of PD patients (Ku¨hn et al.,
2008), how basal ganglia nuclei are involved in movement plan-
ning and execution (Paradiso et al., 2004), and how certain DBS
targets are involved in emotional processing (Bru¨cke et al., 2007).
Therapeutically, stimulating neuronal populations and
elements to alter pathological baseline activity and thereby
influence local, regional, and up- and downstream projections
is the central unifying principle of DBS treatment regardless of
clinical indication. A theoretically effective target, therefore, is
defined by its relative prominence, functional connectivity, and
role within a circuit driving the target behavior or symptom.
Tracking the behavioral andmolecular consequences of stimula-
tion within these pathological circuits is providing a rich opportu-
nity for discovery.
History of DBS
The first neurosurgical interventions to alleviate abnormal move-
ments or psychiatric disturbances involved the severing or
ablation of neural pathways. Victor Horsley, having performed
removal of the motor cortex to treat chorea (Horsley, 1890),
achieved cessation of the abnormal involuntary movement
(albeit by producing paralysis) and is generally regarded as the
father of functional neurosurgery. In 1935 at the second Interna-
tional Congress of Neurology in London, UK, James Fulton
described that making lesions in the frontal lobes of nonhuman
primates resulted in the attenuation of aggressive behavior.
Portuguese neurologist Egas Moniz, who attended the meeting,
returned to Lisbon, where with neurosurgeon Almeida Lima, he
rapidly translated this procedure to psychiatric patients,
producing striking improvements in their aggressive behavior
(Moniz, 1936). These pioneering operations, in an era in which
there were little treatment options, led to the widespread use
of neurosurgery to treat psychiatric disturbances and eventually
to the awarding of the 1949 Nobel Prize in Medicine and, February 6, 2013 ª2013 Elsevier Inc. 407
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Figure 2. Registered Phase I to Phase III
DBS Trials that Are Ongoing and Enrolling
Patients, as of September 2012
A phase I trial tests a new drug or treatment for the
first time in humans and is primarily a safety and
feasibility study. A phase II trial expands the phase
I trial to a larger group of patients to test for
possible efficacy. A phase III trial tests a new
treatment against a placebo and/or a currently
accepted ‘‘gold-standard’’ treatment, in order to
establish the efficacy of the new treatment and to
make recommendations on its use. All data were
obtained from the United States National Institutes
of Health (http://www.clinicaltrials.gov). PD+,
Parkinson’s disease plus an additional disorder
(tremor, depression, dystonia); DLB, dementia
Lewy body; MDD, major depressive disorder; TS,
Tourette’s syndrome; MS, multiple sclerosis; PD,
Parkinson’s disease; OCD, obsessive-compulsive
disorder; ET, essential tremor.
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stereotactic frame-based surgery made possible more precise
interruption or ablation of neural structures starting in the
1940s (Spiegel et al., 1947). Over the next three decades, stereo-
tactic surgery was applied principally to make lesions in basal
ganglia and thalamic nuclei in patients withmovement disorders,
following the principle of ‘‘neutralizing’’ brain areas that generate
or propagate pathological outputs. A number of procedures,
chief among them pallidotomy, thalamotomy, and subthalomot-
omy, were found to alleviate various signs and symptoms of
Parkinson’s disease, including tremor, rigidity, and akinesia,
without producing the paralysis that accompanied earlier opera-
tions involving interruption of the corticospinal system.
Subsequent years, however, saw a decline in the number of
procedures performed for PD and psychiatric conditions, with
functional neurosurgical procedures all but disappearing. This
was due to two developments that continue to shape the
application of neuromodulation technology today, namely the
development of effective medications, such as chlorpromazine
and levodopa in the 1950s and 1960s, as well as the mounting
backlash against the unchecked misuse of psychiatric surgery.
By the 1980s and 1990s, however, it became clear, particularly
for PD, that many patients showed insufficient benefit with
medical therapy and continued to be disabled or developed
medication-related adverse effects. These developments,
coupled with a better understanding of neural pathophysiology,
improved technology, and advances in brain imaging, have
led to a reappraisal and ‘‘renaissance’’ of functional surgical
approaches and paved the way for DBS.
While the therapeutic uses of electrical stimulation for neuro-
logic and pain disorders dates back to the use of electric eels
in ancient Egypt (Henderson, 2008), the modern era starts with
the implantation of electrodes in laboratory animals in the
1940s and 1950s and experiments on the behavioral effect
of electrical stimulation (Delgado and Livingston, 1948; Olds
and Milner, 1954). From there, there was rapid translation into408 Neuron 77, February 6, 2013 ª2013 Elsevier Inc.human research, with the application of
DBS through temporary electrodes and
external pulse generators in patientswith neuropsychiatric and pain disorders (Heath et al., 1955;
Heath, 1963; Bishop et al., 1963; Schaltenbrand, 1965; Mazars,
1975; Bechtereva et al., 1975; Richardson and Akil, 1977). An
additional impetus for the transition from ‘‘ablation to stimula-
tion’’ was based on the observation during surgery that high-
frequency electrical stimulation applied for brain mapping prior
to lesioning could cause an immediate cessation of tremor in
patients with Parkinson’s disease (Benabid et al., 1987). The
similar physiological effects obtained with stimulation or lesion-
ing led early on to the idea that electrical stimulation produced
a ‘‘reversible lesion’’ of target structures.
The current era ofDBShasbeendrivenprincipally by advances
in the treatmentofmovementdisorders, particularlyPD (Figure1).
Thediscovery of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP) and its use in developing a nonhuman
primate model of PD was a new launching point for modern
experimental surgical therapies using focal lesions and electrical
stimulation to disrupt the pathological activity that emerges with
dopamine depletion and thus restore function (Bergman et al.,
1990; Aziz et al., 1991, Benazzouz et al., 1992). These seminal
observations were rapidly translated to patients, with thalamic
DBS for essential tremor approved by the Food and Drug Admin-
istration (FDA) in 1997 (Benabid et al., 1987; Koller et al., 1997;
Zhang et al., 2010). DBS of the subthalamic nucleus or globus
pallidus (GPi) for the management of PD was approved in 2002
(Limousin et al., 1998; Follett et al., 2010). A Humanitarian Device
Exemption was granted by the FDA for DBS for dystonia in 2003
and for DBS of the anterior limb of the internal capsule for obses-
sive-compulsive disorder (OCD) in 2009. With the realization of
the relative safety and therapeutic effects of DBS, it has now
become amainstream surgical procedure. The cumulative expe-
rience of DBS is now being leveraged and applied to different
brain circuits to study DBS as a potential treatment for other
patient populations. A brief enumeration of potential indications
being pursued for DBS and the stage of clinical investigation for
the various disorders is shown in Figure 2.
Table 1. Possible Contributions to Pathophysiology of Circuit
Dysfunction in Neurological and Psychiatric Disorders
Dysfunction Example(s)
Change in the balance of
excitation and inhibition
Epilepsy (Engelborghs et al., 2000),
PD (Alexander et al., 1986),
and schizophrenia (Lisman, 2012)
Increased firing, increased
bursting, increased synchrony,
and loss of specificity
of receptive fields
PD and dystonia (Lozano et al.,
2002; Filion and Tremblay, 1991;
Lenz et al., 1999)
Abnormal oscillations Four to eight hertz oscillations
producing tremor, beta oscillations
mediating akinesia in PD (Little and
Brown, 2012), alpha in PPN in
PD (Thevathasan et al., 2012),
and gamma in schizophrenia
(Lisman, 2012)
Thalamocortical dysrhythmia Tinnitus, PD, and various
neuropsychiatric disorders
(Llina´s et al., 1999)
Hyper/hypoactivity of specific
nodes within networks
SCC/Area 25 in MDD (Mayberg
et al., 2005) and hippocampus
in schizophrenia (Ku¨hn and
Gallinat, 2011)
Deficits in corollary discharge Schizophrenia (Lisman, 2012)
Default mode dysfunction,
dysfunctional cerebral
glucose utilization
Alzheimer’s disease (Greicius et al.,
2004; Laxton et al., 2010) and
depression (Sheline et al., 2009)
STN, subthalamic nucleus; PD, Parkinson’s disease; PPN, pedunculo-
pontine nucleus; SCC, subcallosal cingulate; MDD, major depressive
disorder.
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ReviewThe Nature of Circuit Dysfunction and Its Treatment
with DBS
The therapeutic premise of DBS is the modulation of patholog-
ical activity within brain networks. Brain network organization
and structure, however, is intrinsically complex, with a number
of characterizing features including small-world topology, highly
connected hubs, and modularity as revealed, for example, using
graph theory analysis (Sporns et al., 2002; Sporns, 2011).
Further, the identification of the networks and their constituent
elements is not only challenging, but the nature of the network
disturbances and their precise localization and dynamic proper-
ties are also incompletely understood. A number of guiding prin-
ciples are emerging however. First, what can start as focal and
relatively well-localized disturbances in neuronal function can
be transmitted through the brain to mono- and polysynaptically
connected structures and regions. This can result in widespread
dysfunction throughout an entire neural network, engaging large
cortical and subcortical territories, leading to pathological
changes in function and behavior. Second, structural and func-
tional neuroimaging as well as electrophysiological investiga-
tions have helped identify and characterize these disturbances
and have pinpointed examples of circuit dysfunction and some
accessible critical nodes. Third, in some cases, neutralizing, dis-
rupting, or, on the other hand, driving activity at these sites can
reestablish the functional integrity and ultimately the effectiveoutput of the involved circuits leading to a clinical benefit (Lozano
et al., 2008). Two seemingly opposite strategies, either driving
activity in underperforming circuits or reducing activity in overac-
tive or ‘‘error signal generating’’ regions may lead to clinical
improvements (Mayberg et al., 2005; Laxton et al., 2010). Fourth,
the clinical effects of DBS depend on changes that are both
immediately adjacent and remote to the area being stimulated
and can occur both acutely and in a delayed and progressive
fashion.
While current evidence suggests that circuit dysfunction is
common to most neurological and psychiatric illnesses, this is
still somewhat speculative and far from being established for
many conditions and the exact or presumed nature of the
dysfunction across disorders and its influence on brain function
and behavior can vary significantly (Table 1). Several theories
have been posed, which have helped furnish proposed models
of pathophysiology for some of the most common brain condi-
tions (Table 2). Importantly, circuit dysfunction models have
provided the impetus for brain-based, precisely targeted inter-
ventions, whose objective is rebalancing or restoration of circuit
activity.While these general principlesmayapply across a variety
of disorders, here they are illustrated by focusing the discussion
on prototypical conditions affecting motor, mood, anxiety, and
cognitive circuits: Parkinson’s disease and other movement
disorders, major depressive disorder, obsessive-compulsive
disorder, and Alzheimer’s disease, with the realization that there
are a variety of other disorders that are newly being considered
as therapeutic targets for DBS (Figure 2).
Parkinson’s Disease, Other Movement Disorders,
and Motor Circuits
PD is among the most common neurodegenerative conditions,
with a prevalence of 1% in adults over the age of 60 (de Lau
and Breteler, 2006). Despite the availability of several classes
of medications, most commonly targeting the loss of dopamine
that is a hallmark of the illness, there remain no enduring and
effective disease-modifying treatment options for the illness.
Patients experience progressive motor symptoms that become
associated with medication-induced motor complications
(motor fluctuations and drug-induced dyskinesias), psychiatric
disturbances (impulse control disorders, depression, and hallu-
cinations), cognitive deficits, and dementia in advanced disease
(Lang and Lozano, 1998).
Experiments in MPTP-treated nonhuman primates have
shown that dopaminergic neuronal loss produces profound
disturbances in the function of various nuclei in the basal ganglia
including increased firing, increased bursting, increased
synchrony, and correlated activity in specific frequency bands,
as well as a tendency toward loss of specificity in neuronal
receptive fields (Mitchell et al., 1987; Filion and Tremblay,
1991). The propagation of these disturbances throughout cor-
tico-striato-thalamic-cortical (CSTC) motor loops (Figure 3A) is
thought to be largely responsible for the major motor manifesta-
tions of PD, which include tremor, rigidity, akinesia, and postural
and gait abnormalities (Wichmann and Delong, 2007). Despite
our increasing knowledge of the various components of this
circuitry, how these changes in neuronal behavior produce clin-
ical symptoms is not well understood. Current hypotheses are
many and include that localized groups of neurons firing inNeuron 77, February 6, 2013 ª2013 Elsevier Inc. 409
Table 2. Neural Circuit Disorders and Postulated Circuit Dysfunction
Disorder Circuit Postulated Circuit Dysfunction
DBS Target(s) Being Studied or that
Could Be Considered
Parkinson’s disease,
essential tremor,
and dystonia
Motor Beta and theta oscillations, GPi overactivity,
STN overactivity, and neuronal bursting
STN, GPi, GPe, VL thalamus, PPN,
and spinal cord
Major depression Limbic Increased activity in OFC, SCC, amygdala,
and VS, failure to downregulate
amygdalar activation
SCC, NAcc, habenula, and medial
forebrain bundle
Obsessive-compulsive
disorder
Motor/limbic OFC hyperactivity and failure of
VS-mediated thalamofrontal inhibition
NAcc, ITP, ALIC, and STN
Tinnitus Auditory Sensory deafferentation, thalamocortical
dysrytmia
Auditory pathways
Tourette’s syndrome Motor/limbic Overactive direct pathway, failure
of thalamocortical inhibition
GPi and CM-Pf
Schizophrenia—positive
symptoms
Executive function,
cognitive, and reward
Thalamocortical dysrhythmia, failure
of saliency networks
Temporal cortex and NAcc
Schizophrenia—negative
symptoms
Motivation, reward,
cognitive, and mood
Mesolimbic/mesocortical dysfunction,
failure to engage anticipatory
hedonic system
NAcc, VTA, and SCC
Alzheimer’s disease Cognitive and
memory circuits
Beta amyloid plaques throughout the
brain, DMN dysfunction, cholinergic
degeneration, and entorrhinal
cortex and hippocampal atrophy
Fornix, entorhinal cortex, hippocampus,
cingulate, precuneus, frontal cortex,
and nucleus basalis
Pain (phantom pain,
deafferentation pain, central
pain, and nociceptive pain)
Sensory systems and
interoceptive awareness
Sensory deafferentation and abnormal
neuronal spontaneous bursting behavior
Sensory pathways, periventricular/
periaqueductal areas, and
cingulate insula
Addiction Reward NAcc sensitivity to reward NAcc
Anorexia nervosa Reward and mood Frontoparietal disconnection, parietal
hypometabolism, insular abnormality,
and SCC overactivity
SCC and NAcc
Epilepsy Various Abnormal excitability and synchrony CM thalamus, anterior thalamic nucleus,
thalamus, and seizure focus
GPi, globus pallidus internus; GPe, globus pallidus externus; VL, ventrolateral; OFC, orbitofrontal cortex; VS, ventral striatum; NAcc, nucleus accum-
bens; DLPFC, dorsolateral prefrontal cortex; ITP, inferior thalamic peduncle; ALIC, anterior limb of internal capsule; CM-Pf: centromedian-parafascic-
ular; VTA, ventral tegmental area;DMN,defaultmodenetwork; STN, subthalamicnucleus;PPN,pedunculopontine nucleus;SCC, subcallosal cingulate.
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Reviewsynchrony with 4–8 Hz oscillatory behavior leads to tremor, while
oscillation in the beta band (15–30 Hz) may be responsible for
akinesia (Ku¨hn et al., 2008; Little and Brown, 2012). Inhibition
of the locomotor pedunculopontine nucleus (PPN) region in the
brainstem through overactive descending inhibitory GABAergic
axons from the internal segment of the globus pallidus may
contribute to gait disturbances (Pereira et al., 2008; Thevathasan
et al., 2012; Hamani et al., 2011a). Disturbances in the appro-
priate selection of motor programs and loss of center-surround
inhibition may contribute to the cocontraction of muscles that
may contribute to slowness and rigidity (Mink, 1996). Of the
major symptoms, however, the pathophysiology of rigidity is
perhaps the least well understood.
DBS is being applied to different nodes of the motor circuit for
different features of PD (Figure 3A). GPi and STN are typically
selected for patients with prominent rigidity, akinesia, tremor,
motor fluctuations, and dopamine-related involuntary move-
ments. DBS in these structures has been found to produce
significant and long-lasting benefits (Castrioto et al., 2011;
Oyama et al., 2012). Patients suffering from tremor-dominant410 Neuron 77, February 6, 2013 ª2013 Elsevier Inc.PD typically undergo thalamotomy or DBS of the ventral interme-
diate nucleus (Vim) of the thalamus, the same target used in
patients with essential tremor (ET) (Savica et al., 2011). While
the STN and GPi DBS targets are perhaps similarly effective
treating the major motor manifestations, neither provides suffi-
cient and enduring benefit for the gait and postural disturbances
seen in PD. The PPN, a brainstem structure critical for posture
and gait that receives both basal ganglia and spinal cord feed-
back, is a newer potential target selected in patients with
postural instability and frequent falls (Pahapill and Lozano,
2000; Pereira et al., 2008, 2011; Benabid and Torres, 2012). Early
reports suggest that unilateral PPN stimulation in PD patients
with gait disturbances can lead to less falling and greater
postural stability (Stefani et al., 2007; Ballanger et al., 2009; Wil-
cox et al., 2011). Functional imaging studies show that PPN DBS
results in strong activation of the intralaminar thalamic nuclei and
the cerebellum, providing clues to the possible mechanism of
action of stimulation in this region (Ballanger et al., 2009).
Modulating motor circuits with DBS in PD patients has yielded
significant benefit, but there remain several questions currently
Neuron
Reviewunder active investigation. It is not yet clear, for example, how the
clinical benefit with DBS is achieved, and why some symptoms
(e.g., tremor) respond more quickly than others (e.g., gait and
postural disturbances). Further, although efforts are being
made to individualize targeting and stimulation parameters, it is
unclear what the optimal stimulation settings should be for
each patient, and this remains at present somewhat burden-
some and, to a certain extent, an ‘‘art’’ as well as a science.
Facilitation of stimulation parameter testing and selection could
be potentially improved in a number of ways including through
careful imaging detailing the exact position of electrode contacts
in the brain, modeling the spread of the electrical current
fields (McIntyre et al., 2004), the identification of physiological
changes with stimulation that are predictive of long-term benefit,
and the development of more automated algorithms to optimize
stimulation settings.
Unfortunately, with time and disease progression, the majority
of PD patients develop a number of symptoms, including
speech, gait, and cognitive impairment, that are largely resistant
to currently available medications and DBS surgery (Hely et al.,
1999, 2005). More research is needed to elucidate the pathogen-
esis of these nonmotor and dopamine-resistant symptoms of PD
and the potential impact of DBS on them. There is an increased
awareness that the neural substrates mediating the major motor
manifestations are separate and distinct from those responsible
for the psychiatric and cognitive disturbances. Indeed for multi-
symptomatic disorders such as PD, the concept of multifocal
DBS targeting, for example, implanting stimulating electrodes
in both a motor and a cognitive node, is starting to emerge
(Aarsland et al., 2012; Uitti, 2012).
DBS of the Vim nucleus of the thalamus is also well established
to treat patients with ET, producing important and long-lasting
reductions in tremor and improvements in quality of life (Hubble
et al., 1996; Koller et al., 2001). There are a number of intriguing
observations in ET patients including the delayed loss of benefit
of DBS in some patients (Kumar et al., 2003). Further, and
perhaps more perplexing, is the observation in a small number
of patients that after an extensive period of stimulation, they
obtain seemingly permanent suppression of their contralateral
arm tremor without requiring ongoing stimulation (Kumar et al.,
2003). The explanation for this curious finding is uncertain, but
this could be related to changes in neural activity as a conse-
quence of prolonged stimulation or a progressive DBS-induced
lesion producing, in effect, a ‘‘therapeutic’’ thalamotomy lesion.
Long-term post mortem studies in patients receiving DBS,
however, suggest that stimulation produces little overt reaction
in the neuropil, and there is no evidence for progressive lesions
with prolonged stimulation (Haberler et al., 2000).
DBS is also being used to treat a number of other movement
disorders including primary and secondary dystonia, a variety
of other tremor disorders such as multiple sclerosis-associated
tremor (Brice and McLellan, 1980) or tremor after stroke or
head injury (Lyons and Pahwa, 2008), and neurodegenerative
diseases with associated movement disorders including
Huntington’s disease (Moro et al., 2004; Kang et al., 2011),
pantothenate kinase-associated neurodegeneration (PKAN)
(Castelnau et al., 2005; Mikati et al., 2009), X-linked dystonia or
Lubag (Evidente et al., 2007;Wadia et al., 2010), fragile X (Leeheyet al., 2003; Senova et al., 2012), and some spinocerebellar
ataxias (Freund et al., 2007). In each of these disorders, various
stations along the basal ganglia loop have been targeted with
DBS including the thalamus, the globus pallidus, the subthala-
mic nucleus and their associated afferent, and efferent projec-
tions with variable clinical benefit (Figure 3A).
Of these movement disorders, the FDA has granted Humani-
tarian Device Exemption, and there is the most information for
DBS in dystonia. Dystonia is characterized by involuntarymuscle
contractions that cause slow repetitive movements or abnormal
postures. The evidence for pathological activity in dystonia is
accumulating and includes abnormalities in network functioning
discovered by functional imaging, local field potentials, and
evidence of abnormal activity and maladaptive plasticity in
cortical and subcortical areas and individual neurons (Cebal-
los-Baumann et al., 1997; Lenz et al., 1999; Silberstein et al.,
2003; Asanuma et al., 2005; Carbon et al., 2010). The benefits
of DBS can be particularly striking in patients with primary dys-
tonia (Kumar et al., 1999; Vidailhet et al., 2005; Isaias et al.,
2009; Haridas et al., 2011). In many of these patients, in contrast
to DBS for PD, improvements are delayed by days to weeks and
progress over time. Themechanism responsible for variable time
course of these responses are not well understood but could
include the need for changes in musculoskeletal function, the
process of motor relearning after a prolonged period of motor
disuse or dysfunction, or reflect the temporal profile of the under-
lying plastic changes in circuit organization or efficacy that have
occurred as a consequence of stimulation. Equally interesting is
that in some patients, dystonic symptoms can return almost
immediately upon stimulation cessation, while in others the clin-
ical benefits last days or weeks (Cif et al., 2012; Stavrinou et al.,
2012).
DBS for Psychiatric Disorders
The success of DBS in treating movement disorders has served
at an impetus to revisit neurosurgery for psychiatric disease. The
reversibility and adaptability of DBS increase its appeal and its
acceptance over lesion surgery, particularly in this group of
patients with increased vulnerability. Significant challenges arise
when applying DBS to psychiatric disorders, however, including
the scarcity of predictive animal models, the incomplete under-
standing of the neuroanatomical substrates generating symp-
toms, the missing information on connectivity and network
properties, and the ethical challenges in conducting clinical trials
in psychiatric patient populations (Rabins et al., 2009; Schlaepfer
and Fins, 2010; Fins et al., 2011a; Lipsman et al., 2012). While
DBS is being studied in a number of psychiatric conditions,
including addiction (Kuhn et al., 2011), eating disorders (Lipsman
et al., 2013), and Tourette’s syndrome (Vandewalle et al., 1999;
Porta et al., 2012), here we focus on two major disorders: major
depression and OCD.
Major Depressive Disorder and Mood Circuits
MDD is the most common psychiatric condition, with a lifetime
prevalence of 16% (Kessler et al., 2003). Several theories related
to the psychological, social, biological, and biochemical under-
pinnings of depression have been proposed, and treatments
are typically aimed at ameliorating these specific disturbancesNeuron 77, February 6, 2013 ª2013 Elsevier Inc. 411
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patients benefit from these approaches, a substantial number,
up to 35%, do not and are deemed to have treatment-resistant
depression (Kennedy et al., 2001; Kupfer et al., 2012). As in
PD, surgical treatments, ranging from ablation to noninvasive
transcranial stimulation and DBS, have evolved to manage
patients with treatment-resistant MDD for whom conventional
therapy has failed (see Holtzheimer et al., 2012 for review).
Here, too, an improved understanding of the neural circuitry of
mood has led to hypothesis-driven targets for DBS intervention
that mirror the major symptoms of the illness (Figure 3B).
MDD is a multifaceted illness. The clinical picture can include
symptoms affecting motor and vegetative function (psycho-
motor retardation or agitation, sleep, and appetite), mood and
cognition (affect, attention, and concentration), perceptual (guilt,
biases, and judgments), and reward (anhedonia) systems. With
this diverse constellation of symptoms crossing multiple
domains, it seems unlikely that the illness can be ascribed to
dysfunction of a single anatomic structure, circuit, neurotrans-
mitter system, or gene. It has also become clear that MDD
involves a complex biological-environmental interaction that
requires a multilayered approach to treatment (Keitner and
Mansfield, 2012). Because the diversity of symptoms is greater,
the animal models are less informative, and the pathophysiology
less well known, and perhaps because the function of the
cortical components of the putatively dysfunctional circuits is
less well understood, mood disorders are more complex to
model and understand than motor disorders.
Functional neuroimaging is a strong driver of progress in
psychiatric disease. It does this by revealing the location of
dysfunctional brain areas, giving insights into the nature of the
physiological disturbance, and identifying new potential targets
for intervention, all of which can lead to hypotheses-driven
approaches to experimental DBS therapeutics. Such studies
test whether the functional abnormalities observed in patients
can be recalibrated or reversed with stimulation and whether
the induced changes can be correlated with clinical improve-
ment. One specific example of this principle is the identification
of the subcallosal cingulate area, a brain region activated by the
induction of sadness, which is hypermetabolic in MDD patients
compared to healthy age-matched controls (Mayberg, 1997;
Damasio et al., 2000; Mayberg et al., 2005). This was the firstFigure 3. Circuit Diagrams and DBS Targets for Motor, Mood, Anxiety
Diagrams shown are simplified schematics with not all possible, or known, co
disorders, such as Parkinson’s disease, major depression, obsessive-compulsive
use or evaluation. Only thalamic, GPi, and STN DBS targets are currently approv
(A) Direct, indirect, and hyperdirect pathways through the basal ganglia, with pro
(B) The heterogeneous clinical picture of major depression is probably governed b
cognitive functions (‘‘top-down’’), striatal and basal ganglia structures influencin
and autonomic features (‘‘bottom-up’’). There is also overlap in the circuits govern
other components of the limbic basal ganglia, as well reciprocal connections with
at the core of OCD.
(C) Representation of the main components of the Papez circuit is shown. The f
governingmemory and cognition. Neocortical projections from cingulate to compo
the hippocampal formation. The portion of the fornix beyond the anterior comm
projection from the mammillary bodies to the anterior thalamic nucleus is known
OFC, orbitofrontal cortex; DLPFC, dorsolateral prefrontal cortex; vmPFC, ventra
cortex; MD, mediodorsal; VS/NAcc, ventral striatum/nucleus accumbens; SMA, s
area; GPe, globus pallidus externus; PPN, pedunculopontine nucleus; SNc, sub
internus.potential DBS target for psychiatric disease tested on the basis
of functional imaging.
Identifying the neuroanatomical substrates mediating the clin-
ical manifestations of MDD across cognitive, affective, reward/
motivation, and limbic domains poses a challenge with treat-
ments having to address the dysfunction across these multiple
brain areas (Figure 3B) (Anderson et al., 2012). Intervention in
the subcallosal cingulate region, for example, a hub where
several white matter pathways converge, could theoretically
influence several depression domains: reward dysfunction
through projections to nucleus accumbens, cognitive dysfunc-
tion through reciprocal projections to frontal cortical regions,
and autonomic/vegetative dysfunction through primary hypo-
thalamic, insular, and amygdalar connections (Figure 3B).
In parallel with the circuits becoming better characterized, the
nature of the dysfunction within these circuits in MDD is also
currently an area of active investigation, but much work remains
(Tables 1 and 2). Various observations have been made, ranging
from focal atrophy and volumetric losses in, for example, the
hippocampus and the subcallosal area to dysfunctional meta-
bolic activity as well as neurochemical and neurophysiologic
deficits at the single-neuron to neuronal ensemble level (Price
and Drevets, 2012; Palazidou, 2012; Broadway et al., 2012). To
date, there are few studies examining single-unit or local field
potentials in prominent mood circuit structures. Studies have
explored decision-making conflicts as well as reward-associ-
ated behavior in conjunction with neuronal recordings from
anterior and midcingulate, as well as reward-circuit structures
(Cohen et al., 2009; Sheth et al., 2012). This is an area that is
ripe for further exploration and that will shed more light on
the underlying mechanisms of circuit dysfunction in MDD.
Such research may help also predict which patients are more
likely to respond to DBS or help to personalize the choice of
therapeutic target for each patient. In one recent example,
neurophysiologic studies that have combined SCC DBS in
MDDwith electroencephalogrampre- and postoperatively found
that pretreatment (baseline) alpha-theta concordance predicted
response to DBS treatment (Broadway et al., 2012).
Currently, all DBS targets for depression are investigational,
and these include the subcallosal cingulate (SCC), nucleus
accumbens/ventral striatum (NAcc/VS), inferior thalamic
peduncle (ITP), the medial forebrain bundle (MFB), and habenula, and Cognitive Pathways
nnections shown. Circuitopathies affecting these pathways result in clinical
disorder, and Alzheimer’s disease. DBS at areas with an asterisk are in current
ed for PD. Other targets and disorders are investigational.
jections back to the neocortex.
y reciprocal projections between typically frontal cortical structures, governing
g reward/motivation, and limbic/autonomic projections influencing vegetative
ing disorderedmood and anxiety. For example, projections fromOFC to VS and
amygdala and anterior cingulate, are believed to underlie the pathologic anxiety
ornix represents the principle outflow from hippocampus to limbic structures
nents of the default mode network (parietal, temporal, and frontal) feed back to
issure is known as the postcommissural fornix and is shown in green. The
as the mammillothalamic tract and is shown in red.
l medial prefrontal cortex; SCC, subcallosal cingulate; ACC, anterior cingulate
upplementary motor area; M1, primary motor area; S1, primary somatosensory
stantia nigra compacts; SNr, substantia nigra reticulata; GPi, globus pallidus
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Review(Hab) (Figure 3B). Clinical results over the last decade have been
promising, providing some relief to patients who have failed
conventional therapy, including electroconvulsive therapy
(ECT). The DBS target for depression with the most data to
date is the SCC, initially proposed and piloted in 2005 (Mayberg
et al., 2005). PET imaging has shown that DBS applied in the
SCC region in MDD patients reverses functional abnormalities
including driving down local hyperactivity and modulating
remote cortical targets of local and nearby axonal pathways
to recalibrate the activity (Mayberg et al., 2005). Follow-up of
the first 20 patients showed a 60% response rate (defined
as >50% reduction in Hamilton Depression Rating Scale scores)
at 6 months postoperatively, with 55% of patients responders at
1 year (Lozano et al., 2008). At 3 years follow-up, response and
remission rates were 60% and 50%, respectively (Kennedy
et al., 2011). Results from two additional centers corroborated
the results of the initial study, with one group reporting 58%
and 92% remission and response rates at 2 years and another
group 62.5% and 50% at 1 year, respectively (Puigdemont
et al., 2011; Holtzheimer et al., 2012). On the other hand, a multi-
center study with 21 patients showed much less favorable
outcomes with only 29% of patients responding at 1 year
(Lozano et al., 2012). The true therapeutic benefits are thus not
clearly established or defined and reason for the variability
across studies has yet to be determined. Further insights and
a more accurate appraisal of the value of DBS of the SCC will
require a randomly assigned ‘‘on’’ versus ‘‘off’’ stimulation-
controlled trial. Such a design is currently being studied in
a double-blind, crossover, phase III study in which approxi-
mately 200 patients with MDD who fulfill entry criteria receive
DBS implant and are randomly assigned to receive active or
sham stimulation for 6 months, with all patients subsequently
receiving active stimulation. Another site, the ventral striatum/
nucleus accumbens, a prominent node in the affect and reward
circuit, has been proposed as a target of DBS inMDD.One group
has reported rates of response of 50% at 1 year, with PET data
suggestive ofmodulation in the broader affective circuit involving
the vmPFC and SCC (Bewernick et al., 2010). Reversal of PFC
hypometabolism as well as increased metabolism in ventral
striatum was found after 1 week of DBS of the nucleus accum-
bens (Schlaepfer et al., 2008). These results have supported
additional trials of NAcc DBS as well as associated structures
in the reward-dopaminergic system, including DBS of themedial
forebrain bundle. Other targets explored in MDD include the
inferior thalamic peduncle and the lateral habenula, both of
which have seen promising results but in a very small number
of patients (Sartorius et al., 2010; Jime´nez et al., 2012; Hoyer
et al., 2012). Which DBS targets are best suited for which
patients is a central problem to be resolved.
There are several unanswered questions in the DBS for MDD
field, many of which are common in other indications. It remains
unclear, for example, why some patients appear to respond to
DBS while others do not. Heterogeneity of the illness, the lack
of a universal definition of ‘‘treatment resistance,’’ and individual
anatomical variations in neural pathways, network architecture,
and function are likely contributory. Patient selection would be
helped by specific clinical, neurophysiologic, and/or anatomic
predictors of response. In a recent example, SCC overactivity414 Neuron 77, February 6, 2013 ª2013 Elsevier Inc.has been suggested as a marker of ultimate response to DBS
in MDD (Pizzagalli, 2011). Also puzzling is the observation that
the antidepressant effects of DBS is often not immediate but
delayed and progressive over a period of 3 to 6months, suggest-
ing complex, long-latency mechanisms of action. Additional
questions relate to optimal stimulation settings, specifically
high (greater than 100 Hz) versus low frequency, the necessity
of bilateral stimulation, the mechanism of action, and the selec-
tion of a single, or multiple, targets to be used in tandem to
address different subcircuits and symptoms. Advances in animal
models of DBS for depression may help in addressing these
issues (Hamani et al., 2010; Hamani and Temel, 2012).
Obsessive-Compulsive Disorder and Anxiety Circuits
OCD, with a prevalence of 1%–3%, is among the most common
anxiety disorders (Bourne et al., 2012). Its clinical heterogeneity
and high levels of treatment resistance alsomake it a challenging
condition to treat. OCD includes both a cognitive component,
with persistent anxiety-generating obsessions (e.g., cleanliness),
as well as a motor component, with time-consuming and
disabling compulsions (e.g., washing). The most effective treat-
ments to date involve a combination of serotonin reuptake
inhibition and psychotherapy (McGuire et al., 2012). Unfortu-
nately, as in MDD, a substantial proportion of patients remain
symptomatic despite optimization of treatment.
Neuroimaging studies have helped elucidate the neural
circuitry of OCD, supporting a model of network dysfunction
wherein frontal cortical structures, such as those involved in
decision making, project to, and receive feedback from, corre-
sponding basal ganglia nuclei involved in reward and action
selection pathways (Bourne et al., 2012) (Figure 3B). Importantly,
structures outside of the traditional CSTC circuit have been
implicated in a more extensive network including the anterior
cingulate and amygdala, highlighting the challenges of attrib-
uting OCD symptoms to a single dysfunctional circuit (Milad
and Rauch, 2012). Consistently implicated structures include
the orbitofrontal cortex (OFC), anterior cingulate cortex (ACC),
and caudate, which show metabolic differences compared to
controls, both at rest and in response to provocative stimuli
(Swedo et al., 1992; Perani et al., 1995; Saxena et al., 1999,
2004). The involvement of basal ganglia structures in OCD
underscores its unique place among the anxiety disorders and
may be a clue about its underlying pathogenesis. For example,
OCD is frequently comorbid with neuropsychiatric conditions
such as Tourette’s syndrome, and OCD-type behaviors are
prevalent in patients with striatal and basal ganglia pathology
(Cummings and Frankel, 1985; Laplane et al., 1989; Maia et al.,
2008). Although OFC hyperactivity is among the most reliable
associated findings in OCD patients, it remains unclear how
structural and functional changes in OFC and its projections
translate into OCD symptoms. Also undetermined is whether
activity detected in any structure is the cause of ongoing obses-
sions or the consequence of an attempt to suppress unwanted
thoughts and behaviors (Maia et al., 2008). Notwithstanding,
converging evidence points to a relatively parsimonious
collection of structures whose dysfunction, whether locally or
as a result of up- or downstream effects, is associated with
OCD symptoms. Several of these structures have been the
targets of DBS therapy, and a number of studies have been
Neuron
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to date include the STN, anterior limb of the internal capsule
(ALIC), inferior thalamic peduncle (ITP), ventral caudate/striatum
(VC/VS), and nucleus accumbens (Greenberg et al., 2006; Okun
et al., 2007; Mallet et al., 2008; Jime´nez-Ponce et al., 2009; Huff
et al., 2010) (Figure 3B). These are in general early studies that
involve relatively small numbers of patients. There is no clear
indication as to which target may be better suited to which
patient or which symptoms. For example, a placebo-controlled,
double-blind study of DBS in OCD using the STN target found
a 31% decrease in Yale-Brown Obsessive Compulsive Scale
(YBOCS) score between active and sham stimulation groups
(Mallet et al., 2008). Using a modified definition of treatment
response (>25% reduction in YBOCS), this group reported
12/16 patients responded to stimulation at follow-up. A more
stringent definition of response (>35% reduction in YBOCS)
was used in other studies exploring additional DBS targets, in
which rates of response in open label studies were 66.7% for
ventral striatum/capsule (Goodman et al., 2010) and 56% for
nucleus accumbens (Denys et al., 2010). The similar rates of
response across these and other targeted structures along the
orbitofrontal-striato-thalamic loop could suggest common
effects of DBS and perhaps similar circuitry being influenced
(Jime´nez-Ponce et al., 2009).
The clinical manifestations of OCD are heterogeneous. Some
patients are, for example, hoarders and others are checkers, and
the neural substrates for the various symptoms are beginning to
be understood and localized (Mataix-Cols et al., 2004; An et al.,
2009). This heterogeneity contributes to the complexity of treat-
ing this disorder and several important questions remain. It is
unclear, as inMDD,whether all patients with OCD should receive
the same procedure, or whether a tailored DBS approach is
required for different subcategories of illness. There is an impor-
tant need for more functional imaging studies and animal models
of DBS in order to help elucidate pathways and mechanisms in
OCD and other psychiatric disorders (Hamani and Temel, 2012).
Alzheimer’s Disease and Memory/Cognitive Circuits
Over 5 million people in North America have AD. The progressive
disorder is characterized by various pathological processes
including regionally specific and sequential brain atrophy,
amyloid deposition, intraneuronal neurofibrillary tangles, and
synaptic loss (Ballard et al., 2011). Through mechanisms that
are incompletely understood, these processes lead to wide-
spread network dysfunction including deficits in function of the
default mode network of the brain and the progressive decline
in glucose utilization in specific brain areas as the disease
advances (Herholz et al., 2007; Ballard et al., 2011; Jones
et al., 2011; Schwindt et al., 2012). Treatments in current use
act by increasing cholinergic or antagonizing glutaminergic
transmission (Massoud and Le´ger, 2011). These measures are
only mildly and temporarily beneficial. More effective therapies
are clearly needed.
Two new approaches using DBS in Alzheimer’s disease are
currently being examined. In one approach, first attempted in
1985, DBS is being applied to the nucleus basalis of
Meynert to modulate cholinergic function (Turnbull et al., 1985)
(Figure 3C). This approach is based on the notion that increasing
cholinergic tone, the same mechanism of action as the acetyl-cholinesterase inhibitors in the principle class of drugs used in
AD, could produce improvements in cognitive function. DBS of
the nucleus basalis is currently in phase I clinical trials and there
are no publications to date. The second approach involves DBS
of the circuit of Papez, a series of interconnected brain areas
important in the control of memory (Figure 3C). In a small phase
I clinical trial, DBS was used to drive activity within memory and
cognitive circuits by stimulating the fornix of six patients with AD
(Laxton et al., 2010). This approach considers AD from the stand-
point of being a circuit disorder in which localized dysfunction
arising secondarily to AD pathology has long-reaching conse-
quences transmitted across an extensive brain network. To
date, the investigators have shown that fornix DBS drives activity
transynaptically across the circuit of Papez and the default mode
network (Laxton et al., 2010). In addition, they have shown that
the progressive decline in glucose utilization in temporal and
parietal brain areas that is characteristic in AD can be slowed
down or partially reversed (Smith et al., 2012). These observa-
tions suggest that the network dysfunction in AD may arise, at
least in part, as a consequence of impaired synaptic inputs or
activity to deafferented regions, particularly temporal and pari-
etal areas of the cortex. DBS may be able to modulate these
dysfunctional circuits and change the pattern and level of
synaptic output leading to an augmentation in the activity of
cortical areas within the network. The implication is that at least
a portion of the dysfunction of cerebral cortical areas in AD may
be reversible and, by extension, that restoring activity in the
cortical fields could be accompanied by an amelioration of
cognitive decline or a return of memory and cognitive function.
Of interest, recent observations in patients with epilepsy have
shown that entorhinal stimulation may enhance certain aspects
of memory (Suthana et al., 2012). This suggests that this node
in the memory/cognitive circuit could also be considered for
patients with AD and other cognitive disorders.
The early experiments of stimulation within the circuit of Papez
are being informed by concurrent studies in experimental
animals. Using the homologous targets and stimulation parame-
ters used in AD patients, DBS in rodents at various nodes across
this circuit including the anterior nucleus of the thalamus
(Hamani et al., 2011b) and the entorhinal cortex (Stone et al.,
2011b) and fornix (Hescham et al., 2012) is having a number of
behavioral effects including improving performance on delayed
nonmatching to sample tasks and enhancing spatial memory
in normal animals. An unexpected finding is that DBS within
these circuits drives neurogenesis 2- to 3-fold in the subgranular
zone of the hippocampus in mice and rats (Toda et al., 2008;
Stone et al., 2011b). The DBS-induced newly born granule cells
appear to have normal morphology and become physiologically
active, expressing c-fos after behavioral testing, suggesting that
they are capable of being integrated in functional circuits (Stone
et al., 2011a). That the improvements in memory that occur with
DBS are delayed by weeks and can be blocked by antimitotic
agents is consistent with the notion that the augmented memory
is dependent on neurogenesis. While adult humans are known to
have the capacity for hippocampal neurogenesis (Eriksson et al.,
1998), whether neurogenesis is induced by DBS in patients and
whether this phenomenon contributes in any way to the clinical
effects are questions that for the time being remain unanswered.Neuron 77, February 6, 2013 ª2013 Elsevier Inc. 415
Table 3. Proposed Mechanisms of Action of DBS
Mechanism Example Evidence
DBS inhibits the activity of target neurons
Depolarization blockade (K, Na effects) Reduction of GPi activity with GPi stimulation (Wu et al., 2001;
Dostrovsky et al., 2000); firing suppression in STN neurons after
STN stimulation (Toleikis et al., 2012); DBS associated with
increased ATP and activation of adenosine A1 receptors
(Bekar et al., 2008); frequency-dependent modulation of
synaptic function/neurotransmission (Contreras and Llinas, 2001)
Synaptic failure
Neurotransmitter depletion (glutamate)
Hyperpolarization of neuronal cell bodies and dendrites
Release of inhibitory neurotransmitter (GABA; adenosine)
Synaptic inhibition of afferent projections
DBS activates target neurons
Increased glutamate in efferent projection targets Decreased VL thalamus activity with GPi stimulation (activation
of pallidothalamic pathways) (Montgomery, 2006; Montgomery
and Gale, 2008; Anderson et al., 2003); increased GPi activity with
STN stimulation (Hashimoto et al., 2003); increased neurotransmitter
and second messenger release in downstream structures of DBS
target (Benazzouz and Hallett, 2000; Stefani et al., 2005); STN DBS
leads to increase in DA breakdown products (HVA) and increased
SNc neuron firing rates (Walker et al., 2009; Lee et al., 2004)
Increased dopamine in remaining SNc neurons in PD
DBS both excites and inhibits target neurons
Decoupling of soma and axons (inhibition of soma, activation
of axons) (antidromic, orthodromic)
Computational models showing driving of axonal output by
stimulation independent of activity on neuronal cell body
(McIntyre et al., 2004); STN DBS leads to LTP and LTD in rat
STN neurons (Shen et al., 2003); stimulation leads to plasticity
of SNpr neurons in patients with PD (Prescott et al., 2009)
Plasticity (long-term potentiation [LTP], long-term depression [LTD])
DBS disrupts pathologic oscillatory patterns and generates an ‘‘information lesion’’
Replacement of irregular bursting cells with regular high-frequency firing STN DBS and dopaminergic medication reduce beta-band
oscillations in PD (Doyle et al., 2005; Little and Brown, 2012);
DBS disrupts and overrides network-wide pathologic activity
(McIntyre and Hahn, 2010)
Promotion of ‘‘prokinetic’’ frequencies and abolition of pathologic
beta-band frequencies
Produces/generates ‘‘jamming’’ signal
DBS has trophic effects, leads to neurotrophin release, and generates
new neurons (neurogenesis)
Entorhinal cortex stimulation leads to new DG cells that are
functionally incorporated into memory circuits
(Stone et al., 2011a, 2011b)
GABA, gamma-aminobutyric acid; ATP, adenosine triphosphate; SNc, substantia nigra compacta; HVA, homovanillic acid; STN, subthalamic nucleus;
VL, ventrolateral; DA, dopamine; SNpr, substantia nigra pars reticulata; DG, dentate gyrus.
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sham versus active stimulation-controlled arms to test the
potential safety and clinical benefits of this approach in patients
suffering with AD.
Mechanisms and Kinetics of DBS
One of the most controversial aspects of DBS is its proposed
mechanism of action and this remains an area of intense inves-
tigation (Kringelbach et al., 2010). This issue has several facets
including (1) how neural structures generally communicate with
each other on a subcellular, neuronal, and fiber-pathway level;
(2) the types of dysfunction that occur in neural circuit disorders
and how these are affected by neuromodulation; and (3) the
plastic changes that occur in the brain as a consequence of
stimulation.
It is clear from the clinical and functional imaging literature that
focal stimulation has local and remote effects across brain
networks. What is not yet clear is how this influence is achieved
(Table 3). Theories abound and, despite a lack of consensus, it
appears that the initial simplistic view that DBS was merely
producing a physiological block or reversible lesion, based416 Neuron 77, February 6, 2013 ª2013 Elsevier Inc.largely on what can be similar clinical effects of lesioning and
stimulation, is not entirely correct. New models emphasize that
DBS can act by ‘‘jamming’’ pathological activity in networks
and seek to define the nature and mechanism of how stimulation
disrupts pathological activity (McIntyre andHahn, 2010). Further,
while the majority of data have supported the view that DBS
produces a functional lesion, a number of recent observations
suggests that DBS works by driving activity. Stimulation of
axonal pathways in the brain produces a clear positive response,
for example, motor contraction with stimulation of corticospinal
fibers within the internal capsule and the perception of phos-
phenes with stimulation of the optic tract, provide unequivocal
evidence that stimulation is activating these pathways. DBS
experiments showing the synaptic release of neurotransmitters
at distal axonal projections as measured by microdialysis
(Windels et al., 2005) or the physiological effects of DBS at
downstream neuronal targets are consistent with the notion
that DBS activates the output of the stimulated target with the
ultimate effect on the postsynaptic neurons, depending on
whether the stimulated projection is predominantly excitatory
or inhibitory (Dostrovsky et al., 2000; Hashimoto et al., 2003;
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Figure 4. Kinetics of DBS Response
Mechanisms of action for DBS can be divided
according to the neural elements being affected
and the time course of the response. Some clinical
symptoms, such as tremor, respond much more
quickly than other symptoms, such as anxiety,
depression, and dystonia. This may reflect differ-
ences at the microenvironment level immediately
surrounding the DBS electrode and/or more
remote neural components that lie up- or down-
stream.
GABA, gamma-aminobutyric acid; ET, essential
tremor; PD, Parkinson’s disease; OCD, obsessive-
compulsive disorder.
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opposing mechanisms and separate loci of action can be
engaged simultaneously. Indeed, one prominent model has
DBS doing both excitation and inhibition, whereby the soma
and axon are electrically decoupled by DBS, leading to somatic
inhibition and muting of afferents, as well as to axonal excitation
and activation of efferents (McIntyre et al., 2004). Such amodel is
appealing as it provides a parsimonious explanation for the
neurophysiologic findings of downstream activation and intra-
structural inhibition (Johnson et al., 2008).
The seemingly contradictory findings and the challenges
in studying DBS mechanisms arise as a consequence of a
large number of experimental variables including the numerous
approaches (imaging, neurophysiology, microdialysis, and
behavioral readouts), the specific neural elements being studied,
which molecules are released with stimulation (neurotransmit-
ters, ions, and neurotrophins), the local synaptic arrangements,
the nature and mode of stimulation, the current densities that
vary with physical features of the electrodes being used, and,
importantly, the varied latencies (short versus long term) of the
observed effects. The clinical effects are the algebraic sum of
these various elements, some of which trend in the same direc-
tion, others of which operate at cross-purposes.
An important step in understanding the mechanism of action
of DBS is establishing what neural elements in the brain are
excited and determining their relative susceptibility to electrical
stimulation. One can consider the effects on neuronal cell
bodies, axons, and dendrites with the role of glia being increas-
ingly recognized. Depolarization of an excitable membrane
requires flow of electrical charge across that membrane. For
a short-duration stimulus generating a steady transmembrane
current, the charge transferred is proportional to the product of
current and time. Classical teaching (reviewed in Ranck, 1975)
informs us that there is a hierarchy of responsiveness of neural
elements with, for example, myelinated CNS axons having a
chronaxie (a measure of the threshold for excitability) of
50–100 ms activated before cell bodies with a chronaxie in the
range of 200–700 ms. In addition, large axons are activated
before smaller ones and myelinated axons before unmyelinatedNeuron 77ones. Empirical data also indicate that
high currents (approximately eight times
threshold) in close proximity may block
action potentials in axons. The implica-
tion is that neural elements in close prox-imity may be blocked while those a little further away may be
stimulated. In addition, it takes less cathodal current than anodal
to stimulate a myelinated axon and the orientation of the current
in relation to the structure being stimulated is also important, with
the voltage gradient parallel to the axons being most effective.
These concepts are being incorporated in the emerging area of
modeling current flow from the electrodes to the brain environ-
ment where they are placed (McIntyre et al., 2004). Such an
approach will be useful in helping to select stimulus parameters
from a vast number of possible combinations to optimize clinical
benefits and limit stimulation-related adverse effects. This may
also help drive innovative strategies involving electrode design
and new modes of stimulation, for example, varying wave forms
to steer current and provide selectivity for neural elements are to
be preferentially activated or avoided.
The effects of DBS on the local microenvironment are also
being increasingly recognized. Release and/or accumulation of
neurotransmitters or ionic elements from either neurons or glia
including, for example, adenosine, can help explain short-term
changes or lesional-like effects of stimulation but may be difficult
to reconcile with some of the observed long-term changes and
the long latency of clinical responses (Lee et al., 2004; Bekar
et al., 2008; Shon et al., 2010; Chang et al., 2012).
The ‘‘ON’’ and ‘‘OFF’’ kinetics of the clinical effects of DBS are
proving to be at once complex and informative, especially in
discussions surrounding mechanisms of action and response
(Figure 4). While some of the effects of DBS are immediate,
such as the cessation of tremor with the application of thalamic
stimulation, others, including the improvements seen in dysto-
nia, depression, and epilepsy, can be delayed and progressive,
taking weeks or months of stimulation to achieve maximal
clinical benefit. In several disorders, the short or long latency of
the effect is often mirrored by the variable duration of the
washout of the clinical effects. The return of PD tremor when
the stimulation is turned off, for example, occurs nearly immedi-
ately, while there can be ongoing improvements for days to
weeks after the cessation of stimulation in cases of DBS for
depression, epilepsy, or dystonia. Multiple mechanisms each
with corresponding kinetics are likely at play. For example,, February 6, 2013 ª2013 Elsevier Inc. 417
Table 4. Ethical Considerations in DBS Practice and Research
Considerations Example Questions
Patient selection How should ‘‘treatment resistance’’ for
DBS-eligible conditions be defined
(Schermer, 2011; Lipsman et al., 2010b)?
Should DBS be considered a treatment
of ‘‘last resort’’ (Juckel et al., 2009)?
What are the criteria for the development
of DBS trials for novel indications, and
how can these be empirically defined
(Lipsman et al., 2010a)?
Informed consent Do patients understand the difference
between research trials and treatment
(therapeutic misconception) (Fisher
et al., 2012)?
Do patients with refractory neuropsychiatric
conditions have the capacity to consent and,
if not, is proxy consent by a caregiver
or guardian sufficient (Lipsman et al., 2012)?
Governance What measures need to be in place for
oversight and regulation of individuals
and centers performing DBS?
Resource allocation Does the availability of DBS only in
high-volume, expert centers violate the
ethical principle of justice, and how
can access to experimental procedures and
treatment be optimized (Bell et al., 2011)?
Defining outcomes What is the impact of DBS on personality
and personhood (Schermer, 2011; Lipsman
and Glannon, 2012; Gilbert, 2012)?
Special populations What considerations need to be in place
to manage vulnerable or desperate
patients, as well as children with DBS
(Rabins et al., 2009)?
Responsible
publishing
How should results of DBS trials in novel
and established indications best be
communicated to the public (Gilbert
and Ovadia, 2011)?
Do case reports have a place in the DBS
literature and should these, along with
results of larger trials, be submitted to a
formal registry (Schlaepfer and Fins, 2010)?
Conflicts of interest What is the best way to manage the
relationship between clinician researchers
and the DBS industry (Fins and Schiff, 2010;
Fins et al., 2011b)?
Enhancement Should DBS, or other forms of
neuromodulation technology, be used in
otherwise healthy individuals to enhance
‘‘normal’’ function (Mendelsohn et al., 2010;
Lipsman et al., 2011)?
Neuron
ReviewSCC DBS for MDD is often accompanied by an intraoperative
‘‘acute stimulation’’ effect marked by transient improved mood
and increased engagement and motivation that occurs within
seconds of electrode testing. This stands in contrast to the
approximately 2–3 months that are often required to see
maximal clinical benefit on depression with chronic stimulation.418 Neuron 77, February 6, 2013 ª2013 Elsevier Inc.Activation of local elements, release of neurotransmitters, alter-
ations of cerebral blood flow, and autonomic influences may
explain the acute effects, but other mechanisms are required
to account for the more long-term effects.
The lasting changes in the behavior of neural circuits as
a consequence of DBS, as is characteristic of neuroplasticity,
are becoming increasingly recognized. Although their mecha-
nisms are not well understood, they could involve a variety of
processes, including changes in synaptic efficacy, long-term
potentiation and depression, trophic factor release, changes in
connectivity, and the possible induction of neurogenesis
(Figure 4 and Table 3). The time course of the changes occurring
over months could be explained by new pathways being struc-
turally modified or created and/or alternative neural pathways
being recruited or reinforced. As described above, preclinical
models employing DBS of the anterior thalamic nucleus or
entorhinal cortex in rodent models found significant increased
neurogenesis with new neurons functionally incorporated into
established memory circuits (Toda et al., 2008; Stone et al.,
2011b). Pathologic studies, as well as neuroimaging investiga-
tions (Manganas et al., 2007) before and after DBS, will help
elucidate whether this phenomenon occurs in human patients
as well.
Future Directions in Neuromodulation Research
Interest in DBS is growing at an exponential rate and its profound
effects are introducing a number of complex issues and raising
several important and interesting ethical questions (Table 4).
This is prominently at issue in novel, particularly neuropsychi-
atric, indications and in the context of investigational studies,
in which the perceived benefits to the patient and society need
to be weighed against possible risks, and safeguards must be
put in place to ensure the proper use of these technologies in
patients that may be cognitively or judgmentally impaired.
Here, the involvement of a multidisciplinary team with domain
expertise in the condition of interest is critical to aiding patient
selection and facilitating postoperative follow-up (see Rabins
et al., 2009 and Lipsman et al., 2010a for review of other ethical
issues in DBS research). So that the abuses of neurosurgery for
psychiatric conditions of the early days are not repeated, it is
imperative that research teams engaged in DBS for both estab-
lished and emerging indications be mindful of these ethical
challenges and heed the ethical principles of beneficence and
nonmaleficence at every stage of DBS practice, from patient
selection to dissemination of results.
In the years to come, the field of DBS will see improvements
and evolution. Neuromodulation will remain a critical scientific
and clinical tool and we predict that the field will continue to
grow, bringing greater clinical benefits and being applied to
more patients. There will be technological advances, for
example, better electronics, current steering, parameter optimi-
zation algorithms, stimulation delivery that is responsive to
physiological inputs, and the advent of wireless systems to allow
real-time export and analysis of physiologic data captured
from implanted electrodes. Developments in optogenetics
and nanotechnology, utilizing light- and temperature-sensitive
channels, respectively, will also allow a parsing of subcircuits
and modulation of specific pathways, while closed-loop
Neuron
Reviewstimulation systems utilizing physiological or biochemical signal
detection and stimulation that adapts to the circumstance will
providemore tailored and individualized therapy. Further, newer,
less invasive methods, including focused ultrasound and trans-
cranial magnetic and electrical stimulation, will continue to
evolve. These innovations will occur in the context of advances
in the understanding of neurological and psychiatric disease
including better identification of the nature, location, and
dynamic properties of brain dysfunction.
The future of DBS will lie at the interface of several disciplines
including medical device technology development, structural
and functional brain imaging, modeling work, animal experimen-
tation, and experimental human trials. The convergence of
technology and biology, coupled with the ongoing unmet clinical
need, will drive the development of new brain targets, new
clinical indications, and novel methods of neuromodulation.
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